Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer
R. Perets, J. Bar, D. W. Rasco, M. J. Ahn, K. Yoh, D. W. Kim, A. Nagrial, M. Satouchi, D. H. Lee, D. R. Spigel, D. Kotasek, M. Gutierrez, J. Niu, S. Siddiqi, X. Li, J. Cyrus, A. Chackerian, A. Chain, R. A. Altura, B. C. Cho*
Research output: Contribution to journal › Article › peer-review
63Scopus
citations
Fingerprint
Dive into the research topics of 'Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer'. Together they form a unique fingerprint.